Sumant Ramachandra

CIK: 0001439368

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LYEL

Lyell Immunopharma, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

LYEL
Lyell Immunopharma, Inc.
Jun 10, 2026
Award(A)
Option (right to buy)
Direct
9.3K shares-
LYEL
Lyell Immunopharma, Inc.
May 15, 2025
Award(A)
Option (right to buy)
Direct
130K shares-
LYEL
Lyell Immunopharma, Inc.
Mar 21, 2025
Purchase(P)
Indirect
200K shares at avg. $0.58$115K
LYEL
Lyell Immunopharma, Inc.
Oct 31, 2024
Award(A)
Option (right to buy)
Direct
260K shares-

		Type	Shares	Price		Ownership
Jun 10, 2026	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	9,250	-	-	Direct
May 15, 2025	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	130,000	-	-	Direct
Mar 21, 2025	LYEL Lyell Immunopharma, Inc.	Purchase(P)	200,000	$0.58	$115,220	Indirect
Oct 31, 2024	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	260,000	-	-	Direct

1-4 of 4 transactions

About Ramachandra Sumant

Ramachandra Sumant (SEC CIK 0001439368) files insider reports with the SEC as Director of Lyell Immunopharma, Inc. (LYEL).

Signal8 holds 5 ownership filings by Ramachandra Sumant (1 Form 3, 4 Form 4), filed between Nov 1, 2024 and Jun 12, 2026. Those filings report 4 transactions, from Oct 31, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ramachandra Sumant's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Ramachandra Sumant

Jun 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
May 15, 2025: Grant or award of LYEL derivative securities (Form 4, code A).
Mar 21, 2025: Open-market purchase of LYEL shares (Form 4, code P).
Oct 31, 2024: Grant or award of LYEL derivative securities (Form 4, code A).

Other insiders filing for Lyell Immunopharma, Inc. (LYEL)

Aguirre Jarrad Mattieu, Chief Medical Officer
Shook David, Chief Medical Officer
Seely Lynn, President and CEO
Hill Stephen J., Chief Operating Officer
Lee Gary K., Chief Scientific Officer
Bulis Veronica Sanchez, VP, Corporate Controller

How to read Form 4 transaction codes